Skip to main content

Monoclonal Antibody Deal Benchmarks in Neurology

Median Upfront
$354M
Range: $176M - $535M
Total Deal Value
$3.1B
Range: $1.9B - $4.4B
Royalty Rate
12.5% - 20%
Tiered up to 24%
Dev Milestones
$916M
Range: $562M - $1.3B
Model Your Deal

Market Analysis

Monoclonal Antibody therapies in neurology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 monoclonal antibody asset in neurology is $354M, with total deal values reaching $3.1B. Development milestones average $916M, while regulatory milestones contribute $999M.

The neurology monoclonal antibody landscape is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for monoclonal antibody neurology deals range from 12.5% to 20% at the base tier, with tiered escalation reaching 16.5%-24% on blockbuster sales. Commercial milestones averaging $861M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a monoclonal antibody neurology licensing deal?
Based on our analysis, Phase 2 monoclonal antibody licensing deals in neurology average $354M in upfront payments, with a range of $176M to $535M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for monoclonal antibody neurology transactions?
The median total deal value for Phase 2 monoclonal antibody assets in neurology is $3.1B, ranging from $1.9B to $4.4B. This includes development milestones ($916M), regulatory milestones ($999M), and commercial milestones ($861M).
What royalty rates are standard for monoclonal antibody deals in neurology?
Base royalty rates for monoclonal antibody neurology transactions range from 12.5% to 20%, with tiered escalations reaching 16.5%-24% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in monoclonal antibody neurology deals?
Monoclonal Antibody neurology deals allocate approximately 89% of total deal value to milestones. Development milestones ($916M) make up the largest share, followed by commercial milestones ($861M) and regulatory milestones ($999M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Neurology

View

Bispecific Antibody in Neurology

View

Monoclonal Antibody in Oncology

View

Monoclonal Antibody in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included